Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06309537
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-13
First Post:
2024-03-07
Brief Title:
Chemoreflex Sensitivity in HFpEF
Sponsor:
Istituto Auxologico Italiano
Organization:
Istituto Auxologico Italiano
Study Overview
Official Title:
Chemoreflex Sensitivity in Heart Failure With Preserved Ejection Fraction
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHEMO-HFpEF
Brief Summary:
Patients with heart failure and a preserved left ventricular ejection fraction HFpEF almost invariably complain of exertional breathlessness Abnormal cardiac hemodynamics with pulmonary congestion are believed to trigger dyspnea in this patients However some patients may complain of exertional breathlessness which seems to be out of proportion as compared with hemodynamic abnormalities
Chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli including carbon dioxide produced by the organism during exercise Chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction and an increased chemoreflex sensitivity has been linked to symptoms neurohumoral activation breathing disturbances and adverse prognosis
However the clinical correlates and implications of chemoreflex sensitivity in HFpEF have not been accurately studied
We aim to characterize chemoreflex sensitivity in patients with a diagnosis of HFpEF and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics
Chemoreflex sensitivity accounts for the ventilatory responses to a variety of chemical stimuli including carbon dioxide produced by the organism during exercise Chemoreflex sensitivity can be augmented in heart failure with reduced left ventricular ejection fraction and an increased chemoreflex sensitivity has been linked to symptoms neurohumoral activation breathing disturbances and adverse prognosis
However the clinical correlates and implications of chemoreflex sensitivity in HFpEF have not been accurately studied
We aim to characterize chemoreflex sensitivity in patients with a diagnosis of HFpEF and to correlate chemoreflex sensitivity with clinical and hemodynamic characteristics
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None